indapamide Side Effects
Also known as: Lozol
Analysis of 17,199 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
17,199
Death-Related
1,091
6.3% of reports
Hospitalizations
8,087
47.0% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,091 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 194 |
| ACUTE KIDNEY INJURY | 86 |
| DIARRHOEA | 70 |
| CARDIAC ARREST | 61 |
| PNEUMONIA | 61 |
| VOMITING | 52 |
| DYSPNOEA | 49 |
| LACTIC ACIDOSIS | 48 |
| FALL | 45 |
| RENAL FAILURE | 45 |
| ANAEMIA | 42 |
| SEPSIS | 41 |
| FATIGUE | 39 |
| MALAISE | 38 |
| MYOCARDIAL INFARCTION | 38 |
| NAUSEA | 37 |
| ABDOMINAL PAIN | 35 |
| ACUTE RESPIRATORY DISTRESS SYNDROME | 35 |
| HYPERTENSION | 35 |
| INTERSTITIAL LUNG DISEASE | 35 |
Reactions in Hospitalization Reports
Top reactions in 8,087 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| HYPONATRAEMIA | 1,110 |
| ACUTE KIDNEY INJURY | 671 |
| HYPOKALAEMIA | 568 |
| DYSPNOEA | 498 |
| VOMITING | 492 |
| FALL | 477 |
| DRUG INTERACTION | 456 |
| DIARRHOEA | 437 |
| NAUSEA | 426 |
| CONFUSIONAL STATE | 424 |
| HYPOTENSION | 417 |
| DIZZINESS | 403 |
| MALAISE | 379 |
| ASTHENIA | 365 |
| FATIGUE | 332 |
| PNEUMONIA | 313 |
| PYREXIA | 303 |
| ABDOMINAL PAIN | 295 |
| DEHYDRATION | 291 |
| ATRIAL FIBRILLATION | 287 |
Nearby — Related Medications
What the FAERS Data Reveals About indapamide Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 17,199 voluntary reports linked to indapamide and its brand equivalents (Lozol), spanning 2004 through 2025. Of those, 1,091 (6.3%) listed death as an outcome and 8,087 (47.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 58% were female and 42% male; age distribution skews toward 75+, with 4,518 reports in that bracket. The single most reported reaction is hyponatraemia with 1,286 submissions, followed by acute kidney injury and dyspnoea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.